Small bowel adenocarcinoma: understaged and undertreated?

Area of Science:

• Oncology
• Surgical Oncology
• Gastroenterology

Background:

• Primary small bowel adenocarcinoma (SBA) is a rare cancer.
• SBA is known for chemoresistance and aggressive behavior.
• Optimal lymph node (LN) recovery for jejunoileal SBA is not well-defined.

Purpose of the Study:

• To determine the impact of lymph node recovery extent on staging and survival in small bowel adenocarcinoma.
• To evaluate if recovering a minimum number of lymph nodes improves prognostic accuracy.

Main Methods:

• Utilized the SEER database for jejunoileal SBA cases diagnosed between 1995-2005.
• Analyzed patient data based on AJCC stage and the number of lymph nodes recovered.
• Performed multivariate analysis to identify significant prognostic factors for overall survival.

Main Results:

• Overall survival rates varied significantly by stage: Stage I (59.8%), II (39.5%), III (27.0%), and IV (3.2%).
• Recovering ≥10 LNs showed a significant survival improvement in Stage II SBA (61.8% vs. 32.9%, P < .001).
• Multivariate analysis identified LN recovery (≥10 LNs) as a significant factor for overall survival.

Conclusions:

• Current small bowel adenocarcinoma staging appears inadequate.
• Recovering at least 10 lymph nodes is recommended for accurate staging.
• Observed survival improvements in Stage II SBA with adequate LN recovery may indicate prior understaging.